A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005

Inclusion Criteria: * 1\. Documented use of an inhaled corticosteroid for at least 4 weeks prior to the Day 1 (Baseline) visit and at a dose not greater than 500 mcg/day fluticasone propionate inhalation (or equivalent dose for other inhaled corticosteroids). Subjects who enroll in this study SKY2028-3-006 immediately upon completion of study SKY2028-3-005 have automatically satisfied this criterion. Subjects who enroll in this study SKY2028-3-006 after completion of study SKY2028-3-005 within 24 weeks must use inhaled corticosteroid therapy at a dose not greater than 500 mcg/day fluticasone propionate inhalation (or equivalent dose for other inhaled corticosteroids) for at least 4 weeks prior to the Day 1 (Baseline) visit. * 2\. Females of childbearing potential must have a negative urine beta-human chorionic gonadotropin (beta-HCG) pregnancy test at the Day 1 Visit * 3\. Subject is judged to be in good general health as determined by the investigator. * 4\. Demonstrate satisfactory technique in the use of pMDI. Exclusion Criteria: * 1\. Subjects who prematurely discontinued from the study SKY2028-3-005. * 2\. Life-threatening asthma within the past year. * 3\. History of systemic (oral or injectable) corticosteroid use within the past 12 weeks, * 4\. An upper or lower respiratory infection within 4 weeks prior to the Day 1 (Baseline) visit. * 5\. Significant, non-reversible, pulmonary disease (e.g., chronic obstructive pulmonary disease, cystic fibrosis, bronchiectasis). * 6\. Recent history of smoking, alcohol, substance abuse and/or psychiatric illness, * 7\. Subjects who have taken beta-blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, quinidine type antiarrhythmics, or potent CYP 3A4 inhibitors such as ketoconazole within the past 1 week.